Overview

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Insmed Incorporated